

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Austar Lifesciences Limited**  
**奥星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6118)**

**POSITIVE PROFIT ALERT**

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and the information currently available to the Board, the Group is expected to record a profit attributable to the owners of the Company of not less than RMB200 million for the six months ended 30 June 2021, as compared to the profit attributable to the owners of the Company of approximately RMB12.8 million for the six months ended 30 June 2020.

The Board attributes such expected significant increase in profit principally to: (i) the significant growth of revenue and gross profit being recognised for the six months ended 30 June 2021, which was mainly attributable to the higher level of backlog as at 31 December 2020 and the increase in the amount of order-in-take of the Group for the six months ended 30 June 2021; and (ii) the one-off gain recognised from the Group’s disposal of its 60% equity interest in PALL-AUSTAR Lifesciences Limited, a then joint venture of the Group, during the period. Details of such disposal are set out in the circular of the Company dated 23 March 2021 (“**Circular**”). Taking into account the matters as set out in the sub-paragraph “Post-Completion adjustment to the Consideration” of the Letter from the Board contained in the Circular and the estimated expenses and tax in relation the disposal, the one-off net gain from the disposal would be around RMB175 million.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 and is not based on any figure or information which has been audited or reviewed by the Company's auditors and may be subject to adjustments and changes. Details of the Group's financial information and performance will be disclosed when the Group's interim results for the six months ended 30 June 2021 are announced, which is expected to be published in late August 2021.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 16 July 2021

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yüewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*